FFO
ARCT icon

Fortitude Family Office’s Arcturus Therapeutics ARCT Stock Holding History

Fortitude Family Office’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.16K Buy
158
+24
+18% +$251 ﹤0.01% 2000
2026
Q2 		$900 Buy
+134
New +$1.06K ﹤0.01% 1785

Other funds holding ARCT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Fortitude Family Office's ARCT Position: Q3 2026 in Review

Fortitude Family Office increased its Arcturus Therapeutics (ARCT) stake by 18% in Q3 2026, buying an estimated $251 and bringing the position to 158 shares worth $2.16K. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

Fortitude Family Office first reported a position in ARCT in Q2 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Fortitude Family Office held 158 shares of Arcturus Therapeutics worth $2.16K as of Q3 2026.
  • Fortitude Family Office bought 24 Arcturus Therapeutics shares in Q3 2026, an estimated $251.
  • Arcturus Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2000 holding.
  • Fortitude Family Office first reported a position in Arcturus Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.